Randomized Controlled Study of Programmed Weaning From NIV for AECOPD
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Aug 25, 2023
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) gradually stop using noninvasive mechanical ventilation. Noninvasive ventilation is a method that helps patients breathe without needing a breathing tube. The goal of the study is to find a safe process for reducing the time patients spend on this type of support, which could improve their recovery and comfort.
To participate in this trial, individuals must be at least 40 years old and have been diagnosed with an acute worsening of COPD. They should have a specific type of breathing problem that is manageable with noninvasive mechanical ventilation. Unfortunately, individuals who are pregnant, have certain health issues, or are under 40 years old cannot join. Participants can expect to receive careful monitoring and support throughout the trial, and their experiences will help researchers understand the best ways to manage breathing difficulties in COPD patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • It is defined that in patients with acute exacerbation of chronic obstructive pulmonary disease, the arterial blood gas analysis was decompensation of respiratory acidosis, and the pH value was 7.20-7.35
- • Non-invasive mechanical ventilation was performed and it was well tolerated
- Exclusion Criteria:
- • younger than 40 years old
- • pregnancy
- • Human immunodeficiency virus (HIV) antibody was positive
- • Hemodynamic instability
- • Mechanical ventilation for endotracheal intubation and cardiopulmonary resuscitation were disagreed
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Qingtao Zhou
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported